Latest updates for Iviyx

Fresh curated links around IVIYX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Nomura Global Growth Fund Q2 2026 Commentary
  • INVIVYD
  • DIVI: Ahead Of Benchmark, Behind Top Peers

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

seekingalpha.com /4 weeks ago

Nomura Global Growth Fund Q2 2026 Commentary

Read source
cafepharma.com /1 month ago

INVIVYD

INVIVYD Anonymous (not verified) Tue, 08/04/2026 - 21:28 field_thread_url https://cafepharma.com/boards/threads/invivyd.703943/ board na...

Read source
seekingalpha.com /4 days ago

DIVI: Ahead Of Benchmark, Behind Top Peers

Read source
seekingalpha.com /3 weeks ago

Treasury Yields Snapshot: August 14, 2026

Read source
seekingalpha.com /1 month ago

Moving Averages Of The Ivy Portfolio And S&P 500: July 2026

Read source
seekingalpha.com /2 days ago

Voya Infrastructure, Industrials And Materials Fund Q2 2026 Commentary

Read source
seekingalpha.com /5 days ago

Victoria's Secret & Co. (VSXY) Q2 2026 Earnings Call Transcript

Read source
fool.com /1 month ago

What This Invesco Insider Move Signals With the Stock Up 63%

The shares were withheld to cover tax liabilities from restricted stock unit vesting.

Read source
seekingalpha.com /2 weeks ago

Voya Strategic Income Opportunities Fund Q2 2026 Commentary

Read source
seekingalpha.com /6 days ago

VYM: Dividends And Diversification Doing Good Work In 2026

Read source
fool.com /1 month ago

IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

IHE's top two holdings account for over 43% of its portfolio, while IXJ spreads risk across 110 international stocks. Which concentration strategy fits your risk tolerance?

Read source
fool.com /3 weeks ago

VGIT vs. IGIB: Which Bond ETF Offers the Better Buy for Income Investors?

VGIT offers lower volatility and lower fees, while IGIB delivers higher yields and has stronger recent returns. Which fits your portfolio?

Read source
fool.com /2 weeks ago

Which Healthcare ETF Is the Better Buy: Vanguard's VHT or iShares' IXJ?

VHT charges low fees and holds more than 400 stocks for broader diversification. IXJ's portfolio of 110 holdings includes international exposure -- but comes at a higher cost.

Read source
seekingalpha.com /1 week ago

SDVY: Small/Mid-Cap Rising Dividend Achievers ETF Is A High-Quality Choice

Read source
seekingalpha.com /1 month ago

SEI: Buy Before The S&P 600 Flows Arrive

Read source
seekingalpha.com /4 weeks ago

Cumberland's Monday Memo

Read source
seekingalpha.com /1 month ago

IQVIA Holdings Inc. 2026 Q2 - Results - Earnings Call Presentation

Read source
seekingalpha.com /2 weeks ago

The Investor Mentality

Read source
seekingalpha.com /1 month ago

VYMI: A Global Income Play For AI Skeptics

Read source
seekingalpha.com /1 month ago

Income-Covered Closed-End Fund Report, July 2026

Read source
seekingalpha.com /1 month ago

Global Wealth Research - July 2026

Read source
seekingalpha.com /1 week ago

iShares iBonds Dec 2055 Term Treasury ETF declares monthly distribution of $0.0962

Read source
fool.com /1 month ago

Concentrated Pharma Exposure or Broader Global Healthcare? PPH vs. IXJ

The VanEck Pharmaceutical ETF (PPH) gives investors a concentrated way to own major drugmakers, while the iShares Global Healthcare ETF (IXJ) spreads exposure across the wider heal...

Read source
seekingalpha.com /1 month ago

Invesco Earnings Review: Value Has Caught Up

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Iviyx

seekingalpha.com

Recent coverage from public sources
Public source

cafepharma.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

fool.com

Recent coverage from public sources
Public source